Results 51 to 60 of about 2,223,665 (257)
Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer [PDF]
International Journal of Molecular Sciences, 2014 Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signaling activity, downstream apoptotic regulators and ...
Judith Knievel +7 more
openaire +3 more sources
STAR Protocols, 2023 Approaches to study therapy resistance in HCC (hepatocellular carcinoma) are limited, especially when using HCC models in vitro. Here, we present a protocol to establish an in vitro Sorafenib-resistant human HCC cell model and conduct an shRNA-mediated synthetic lethal screen in established Sorafenib-resistant HCC cell lines to identify critical ...
Ruize Gao +2 more
openaire +3 more sources
Autophagy Modulation Attenuates Sorafenib Resistance In HCC Induced In Rats
Cell Death & Disease, 2023 AbstractHepatocellular carcinoma (HCC) has risen as the villain of cancer-related death globally, with a usual cruel forecasting. For advanced HCC, sorafenib has been FDA approved as first line treatment. In spite of the bright potential that sorafenib demonstrated in studies, actual clinical results are limited owing to the massive occurrence of drug ...
Yomna Elleithi +2 more
openaire +3 more sources
, 2022 [[abstract]]Sorafenib is a multikinase inhibitor for the standard treatment of advanced liver cancer patients. However, acquired resistance to sorafenib is responsible for a poor prognosis.
Tseng, CF;Chen, LT;Wang, HD;Liu, YH;Shiah, SG
core +1 more source
Cell Death and Disease, 2023 Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction.
Feng-li Xu +8 more
doaj +1 more source
Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib [PDF]
Cancer Genomics - Proteomics, 2019 The outcome of patients with advanced hepatocellular carcinoma (HCC) remains poor and therapeutic options, including sorafenib, the first anti-cancer drug proved to prolong survival in patients with advanced HCC, are limited. However, no clinically useful predictive biomarker for sorafenib has been reported.We exploited two-dimensional gel ...
Yin-Hsun, Feng +4 more
openaire +2 more sources
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. [PDF]
PLoS ONE, 2017 BACKGROUND:Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase inhibitor for systemic chemotherapy in patients with advanced HCC.
Yuki Haga +7 more
doaj +1 more source
Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter [PDF]
Molecular Cancer Therapeutics, 2014 Mazard and colleagues present results providing evidence that sorafenib favors irinotecan intracellular accumulation and enhances irinotecan toxicity via inhibition of the drug-efflux pump ABCG2 ([1][1]).
openaire +2 more sources
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
Oncotarget, 2016 The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. Accordingly, we established sorafenib-resistant HCC cells and investigated the underlying mechanism of resistance to sorafenib.
Tomonari, Tetsu +10 more
openaire +3 more sources
Molecular Therapy: Nucleic Acids, 2020 In recent years, circular RNAs (circRNAs) have been shown to have critical regulatory roles in the resistance to anti-cancer drugs. However, the contributions of circRNAs to sorafenib resistance in hepatocellular carcinoma (HCC) remain largely unknown ...
Cheng Yang +9 more
doaj +1 more source